Posted by Michael Wonder on 17 Mar 2022
PHARMAC widening access to rituximab and zoledronic acid
17 March 2022 - PHARMAC is widening access to two medicines, rituximab and zoledronic acid, estimated to benefit 1,750 New Zealanders a year.
“PHARMAC is committed to continuing our work to fund more medicines for more people, delivering the best possible health outcomes for New Zealanders from within our fixed budget,” concludes Ms Williams.
Don't get too excited; PHARMAC has only decided to widen access for two patent expired medicines. Not worthy of a press release in any other OECD country.
